CJC-1295 NO DAC/IPAMORELIN (10mg)

What is Dragon Pharma CJC-1295 no DAC/Ipamorelin Blend?
CJC-1295 no DAC/Ipamorelin Blend is a synergistic peptide combination designed to stimulate endogenous growth hormone (GH) release through two complementary mechanisms. CJC-1295 (no DAC) is a modified analog of growth hormone–releasing hormone (GHRH) with a short half-life, intended to promote natural pulsatile GH secretion without prolonged systemic exposure. Ipamorelin is a selective growth hormone secretagogue (GHS) that activates the ghrelin receptor (GHS-R1a), enhancing GH output with minimal influence on cortisol or prolactin. Together, this blend supports amplified yet physiologically aligned GH pulses, making it popular in research focused on lean mass development, recovery, fat metabolism, and endocrine optimization.

Mechanism of Action:
The CJC-1295 no DAC/Ipamorelin Blend works by targeting two distinct receptors within the hypothalamic–pituitary axis. CJC-1295 (no DAC) binds to GHRH receptors on somatotroph cells in the anterior pituitary, increasing the amplitude of natural GH pulses. Because it lacks DAC (Drug Affinity Complex), it has a shorter duration of action, allowing for controlled, pulse-based stimulation rather than sustained elevation. Ipamorelin simultaneously activates the GHS-R1a (ghrelin receptor), triggering an additional GH release pathway. The combined activation results in enhanced secretion of GH, which in turn stimulates hepatic production of IGF-1 (Insulin-like Growth Factor-1). This cascade supports anabolic signaling, protein synthesis, lipolysis, and tissue regeneration. The dual-pathway approach closely mimics physiological GH rhythms while minimizing unwanted hormonal fluctuations.

Benefits:

• Enhances natural pulsatile growth hormone release
• Increases IGF-1 production and anabolic signaling
• Supports lean muscle development and fat metabolism research
• Promotes recovery and tissue-repair investigations

Research Applications:

• Studying synergistic GHRH and GHS receptor activation
• Exploring muscle hypertrophy and connective tissue repair
• Investigating body composition and metabolic adaptation
• Evaluating endocrine axis function and GH pulsatility

Dosing Instructions:

• Dosing: Reconstitute lyophilized blend with bacteriostatic water before administration
• Daily Dose: Common research range 100–300 mcg of each peptide per injection
• Route: Subcutaneous injection
• Duration: 8–16 weeks depending on protocol goals
• Frequency: 1–3 times daily due to short half-life
• Recommended Cycles: Structured cycles with hormonal monitoring between phases
• PCT: Not typically required; assess GH and IGF-1 levels post-cycle

Stacking With Other Products:

• MK-677 (Ibutamoren) for extended GH pathway research
• Hexarelin for advanced secretagogue comparison studies
• IGF-1 LR3 for downstream anabolic pathway evaluation
• GHK-CU for regenerative and connective tissue research

Side Effects:

• Mild water retention
• Temporary flushing or headache
• Injection-site irritation
• Rare transient fatigue

Contraindications:

• Active malignancy due to GH pathway stimulation
• Uncontrolled diabetes
• Pregnancy or breastfeeding
• Untreated pituitary or endocrine disorders

Conclusion
The CJC-1295 no DAC/Ipamorelin Blend offers a strategic dual-receptor approach to enhancing endogenous growth hormone secretion. By combining GHRH receptor activation with selective ghrelin receptor stimulation, it amplifies GH and IGF-1 output while maintaining physiologic pulse dynamics. Its short-acting profile allows researchers to align administration with natural hormonal rhythms, making it highly valuable in studies focused on muscle recovery, metabolic efficiency, and endocrine optimization. When used within structured research protocols and accompanied by proper monitoring, this blend provides significant insight into the regulation and enhancement of the growth hormone axis.

References:

• Bowers CY. "Growth Hormone-Releasing Peptides and Mechanisms of Action." Endocrinology Reviews.
• Teichman SL, et al. "CJC-1295 and Sustained Growth Hormone Elevation." Journal of Clinical Endocrinology & Metabolism.
• Smith RG, et al. "Ghrelin Receptor Agonists and GH Secretion." Trends in Endocrinology & Metabolism.
• Ghigo E, et al. "Synergistic Effects of GHRH and GHS Compounds." European Journal of Endocrinology.

CJC-1295 no DAC/Ipamorelin FAQ

✔️ What is CJC-1295 no DAC/Ipamorelin Blend?
It is a combination of CJC-1295 without DAC and Ipamorelin, designed to stimulate pulsatile growth hormone release safely and effectively.

✔️ How does this peptide blend work?
The blend works by activating ghrelin receptors and the somatotropic axis, boosting GH and IGF-1 levels, which support muscle growth, recovery, and fat metabolism.

✔️ What are the main benefits?
Enhanced muscle growth, improved recovery and repair, increased energy levels, support for fat metabolism, and anti-aging effects.

✔️ How should I store this peptide?
Store unreconstituted vials in a cool, dry place away from light. Once reconstituted with sterile bacteriostatic water, refrigerate at 2–8°C and use within the recommended timeframe.

✔️ What is the typical dosing protocol?
Doses generally range from 100–200 mcg per injection, administered subcutaneously once or twice daily depending on research goals.

✔️ How long are research cycles?
Cycles typically last 4–12 weeks, with rest periods between cycles to allow the body to maintain natural hormone balance.

✔️ Are there side effects?
Most side effects are mild and may include temporary water retention, headaches, or injection site irritation. Serious effects are rare.

✔️ Can this peptide be stacked with others?
Yes, it can be combined with BPC-157, IGF-1 LR3, or AOD-9604 for enhanced muscle growth, recovery, and fat metabolism.

✔️ Is post-cycle therapy (PCT) required?
PCT is not required, as CJC-1295 no DAC/Ipamorelin typically does not suppress natural hormone production.

✔️ Who should avoid using this peptide?
Individuals with active cancer, serious cardiovascular conditions, or hypersensitivity to the peptides should avoid use. Pregnant or breastfeeding individuals should also not use it.

CJC-1295 no DAC/Ipamorelin Blend – Storage & Safety Essentials

Optimal Storage for Peak Potency

Preserve the effectiveness of your CJC-1295 no DAC/Ipamorelin Blend by following proper storage guidelines:

• Keep the vial refrigerated at 2–8°C.
• Protect from direct sunlight, heat, and humidity, which can reduce peptide stability.
• Avoid freezing unless the manufacturer explicitly recommends it, to prevent degradation.

Handling Guidelines for Safety & Integrity

Proper handling ensures user safety and peptide quality:

• Always use sterile syringes and needles for reconstitution and administration.
• Limit freeze-thaw cycles to maintain potency.
• Ensure the vial is tightly sealed to prevent contamination.

Reconstitution Instructions

To maximize stability and performance:

• Reconstitute using bacteriostatic water, gently swirling to dissolve.
• Do not shake vigorously, as this may damage the peptide structure.
• Any unused solution should be stored refrigerated and used within the recommended timeframe.

Safety & Disposal Practices

Follow these steps for safe handling and disposal:

• Work in a clean, controlled environment.
• Dispose of used needles, syringes, and vials according to biohazard safety guidelines.
• Never use the peptide if it appears cloudy, discolored, or contains particles.

Key Takeaway

By following proper storage, handling, and reconstitution practices, your CJC-1295 no DAC/Ipamorelin Blend remains stable, potent, and safe. These guidelines help ensure maximum results while minimizing risk of contamination or peptide degradation.